Cohance Lifesciences' Q2 FY 2025-26 Quarterly Results

Result Summary

• Cohance Lifesciences Ltd reported a 1.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 110.1%.
• Its expenses for the quarter were down by 1.1% QoQ and up 182.8% YoY.
• The net profit increased 43.1% QoQ and decreased 19.0% YoY.
• The earnings per share (EPS) of Cohance Lifesciences Ltd stood at 1.93 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Cohance Lifesciences Ltd is a company operating within the pharmaceutical and life sciences sector. The company is primarily engaged in the development, manufacturing, and distribution of generic pharmaceuticals and other healthcare-related products. It may also be involved in research and development activities aimed at creating innovative solutions within the healthcare industry. However, detailed information about the company's specific product lines or any recent major developments is not available in the provided data. The company's financial performance in the current quarter will shed light on its operational dynamics and market position in the industry.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Cohance Lifesciences Ltd reported a total income of ₹571.17 crores, which represents a quarter-over-quarter (QoQ) increase of 1.4% from ₹563.48 crores in Q1FY26. Year-over-year (YoY), the company experienced a significant increase of 110.1% compared to ₹271.84 crores in Q2FY25. This substantial annual growth in revenue could be attributed to various factors such as increased sales volume, the introduction of new products, or expanded market reach, although specific reasons are not provided in the data.

Profitability

For Q2FY26, the company's Profit Before Tax (PBT) was ₹83.77 crores, reflecting a QoQ increase of 33.5% from ₹62.76 crores in Q1FY26. However, there was a YoY decline of 15.8% when compared to ₹99.50 crores in Q2FY25. The Profit After Tax (PAT) for Q2FY26 stood at ₹66.39 crores, marking a QoQ increase of 43.1% from ₹46.40 crores in Q1FY26, while experiencing a YoY decrease of 19.0% from ₹81.98 crores in Q2FY25. The tax expense for the quarter was ₹17.38 crores, with a QoQ increase of 6.2% and a slight YoY decrease of 0.8%. The Earnings Per Share (EPS) for Q2FY26 was ₹1.93, increasing by 52.0% QoQ from ₹1.27, but decreasing by 39.9% YoY from ₹3.21 in Q2FY25.

Operating Metrics

The total expenses for Q2FY26 amounted to ₹487.40 crores, which is a decrease of 1.1% QoQ from ₹492.62 crores in Q1FY26. On a YoY basis, expenses increased by 182.8% from ₹172.34 crores in Q2FY25. This large YoY increase in expenses may reflect higher operating costs, increased production volumes, or other factors not specified in the data. The data provided does not include specific key financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio. Additionally, the report does not specify any significant trends or anomalies beyond the presented financial metrics.